| Bioactivity | Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB[1]. |
| Invitro | Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2]. |
| Name | Mal-(CH2)5-Val-Cit-PAB-Eribulin |
| CAS | 2130869-21-3 |
| Formula | C69H97N7O19 |
| Molar Mass | 1328.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
Mal-(CH2)5-Val-Cit-PAB-Eribulin
CAS: 2130869-21-3 F: C69H97N7O19 W: 1328.54
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-micr
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.